Krka reported PLN 301.67m consolidated net profit attributable in Q1-Q3 2022, compared to PLN 240.1m profit a year earlier.
The company plans to spend €90m on investments in our own development and production facilities and infrastructure. The amount is lower than the initial plan, but higher than the investment budget of the last two years.
Today we present the valuation of KRKA, prepared by companyvalueradar.com
Krka Group is a Slovenian pharmaceutical company and has been present on the Polish market for almost 40 years. Krka products are present in 70 countries around the world. In 2012, it debuted on the Warsaw Stock Exchange.
In Poland, leading products are cardiovascular drugs, drugs used in the treatment of hypertension, antidepressants, where the market share of these products varies between 10% and 30%.
← Go back